The effect of plerixafor and G-CSF on CD56^brightNK_regpopulations in peripheral blood and bone marrow. (A) Number of CD56^bright NK_reg cells was enumerated from peripheral blood by flow cytometry. Fold change was computed as ratio between number of CD56^bright NK_reg cells after 4 hours of plerixafor administration, 4-daily administration of G-CSF (5 μg/kg), or 4-daily administration of G-CSF (5 μg/kg) followed by plerixafor administration and baseline. Statistical significant difference was determined by the 2-tailed Student t test. (B) Number of CD56^bright NK_reg cells was enumerated from blood and bone marrow by flow cytometry. Fold change was computed as ratio between number of CD56^bright NK_reg cells after 4 hours of plerixafor and baseline. Statistical significant difference was determined by the 2-tailed Student t test. (C) Number of CD56^bright NK_reg cells was enumerated from peripheral blood and bone marrow by flow cytometry. Fold change was computed as (1) ratio between number of CD56^bright NK_reg cells after 4 hours of plerixafor and baseline in peripheral blood; (2) ratio between number of CD56^bright NK_reg cells after 4-daily G-CSF administration and baseline in bone marrow. Statistical significant difference was determined by the 2-tailed Student t test.